Precision BioSciences

138 articles with Precision BioSciences

• Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma

  6/4/2021

  Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells Following Enhanced Lymphodepletion (eLD) - Median Interval of 1 Day from Enrollment to Start of Lymphodepletion

• 

  Global Roundup: BioVersys Secures CARB-X Funds for Multidrug Resistant Research

  6/3/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
• 

  A New $550 Million Life Sciences Venture Capital Fund is in Town

  6/3/2021

  venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.

•  Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

  6/1/2021

  Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021

• Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

  5/27/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company’s Interim Chief Financial Officer

• Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

  5/26/2021

  Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.

• Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting

  5/19/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that additional data from its Phase 1/2a study of PBCAR0191, will be presented at the 2021 American Society of Clinical Oncology (ASCO) Meeting being held virtually June 4-8, 2021.

• Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

  5/13/2021

  - Reacquired Global Development and Commercialization Rights to all Servier Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Expect to Present Updated PBCAR0191 Data in June at ASCO 2021 - Plan to Initiate Phase 1 Study of PBCAR19B Stealth Cell in Patients with R/R NHL by End of May 2021

• New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing

  5/11/2021

  Precision BioSciences, Inc. announced new in vivo data resulting from a preclinical research collaboration with investigators at the University of Pennsylvania presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting.

• Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

  5/6/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.

•  Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting

  5/3/2021

    Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting   Preclinical Research with ARCUS Genome Editing Rejuvenated Rod Photoreceptor Structure and Function in a Transgenic Pig Model of Human Blindness

• Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting

  4/27/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,

• Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

  4/15/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences.

• Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

  4/15/2021

  - Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible to Receive Milestones and Royalties Based on Program Success

• Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

  4/12/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Stanley R. Frankel, M.D. has been appointed as a Director on the Company’s Board of Directors and a member of the Board’s Science and Technology Committee

• Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series

  4/9/2021

  Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.

• Precision BioSciences Announces CEO Transition PlanBegins Search for Next Chief Executive Officer

  4/6/2021

  Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced a Chief Executive Officer transition plan and the initiation of a public search for a new CEO. Matt Kane, Co-Founder and Chief Executive Officer, is expected to continue in his current leadership capacity and as a board member

• Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

  3/29/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.

• Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

  3/18/2021

  Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell, anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma;

• Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

  3/12/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.